PARIS (Reuters) – Vaccines company Valneva said on Friday that it had completed a regulatory submission step with the United States Food & Drug Administration (FDA) for its single-shot chikungunya vaccine candidate, VLA1553.
Chikungunya is a mosquito-borne viral disease. Valneva plans to make regulatory submissions for its VLA1553 vaccine in Europe in the second half of 2023.
(Reporting by Sudip Kar-Gupta; Editing by Christian Schmollinger)
